Biovitrum And Syntonix Dose First Hemophilia B Patient In Clinical Trial Of A Novel Factor IXFc Treatment
Jun 1st 2008Drug InformationBlood
Biovitrum AB (STO: BVT) and Syntonix Pharmaceuticals, Inc., a subsidiary of Biogen/Idec (NASDAQ: BIIB) announced the initiation of a phase I/IIa open-label, dose escalation study of a long-acting, recombinant Factor IXFc (FIXFc) protein in patients with hemophilia B. The study is ongoing at clinics in the United States and will assess the safety, tolerability and pharmacokinetics of Factor IXFc in this patient population.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
